Response of extraabdominal desmoid tumors to therapy with imatinib mesylate.
about
Gardner's syndrome in a 40-year-old woman: successful treatment of locally aggressive desmoid tumors with cytotoxic chemotherapyExtra-abdominal desmoid tumours: a review of the literature.A V530I Mutation in c-KIT Exon 10 Is Associated to Imatinib Response in Extraabdominal Aggressive Fibromatosis.Imatinib: a breakthrough of targeted therapy in cancer.Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up.Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis.Response of progressive fibromatosis to therapy with liposomal doxorubicin.Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG).Desmoid tumors: clinical features and treatment options for advanced diseaseThe Wnt/β-catenin pathway in human fibrotic-like diseases and its eligibility as a therapeutic target.A massive abdominal wall desmoid tumor occurring in a laparotomy scar: a case report.Signal transduction pathway analysis in fibromatosis: receptor and nonreceptor tyrosine kinases.Five years of local control of subscapularis aggressive fibromatosis managed by surgery and imatinib: a case report.Immunohistochemical analysis of desmoid tumours.Evidence for genetic predisposition to desmoid tumours in familial adenomatous polyposis independent of the germline APC mutation.Some lessons learned from imatinib mesylate clinical development in gastrointestinal stromal tumors.Desmoid tumours of the extremities and trunk: a review of the literature.Desmoid fibromatosis in pediatric patients: management based on a retrospective analysis of 59 patients and a review of the literature.Targeting the Notch pathway: A potential therapeutic approach for desmoid tumorsA nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients.KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib.Management of advanced adult soft tissue sarcoma.Aggressive juvenile fibromatosis of the paranasal sinuses: case report and brief review.Molecular targeted therapies in non-GIST soft tissue sarcomas: what the radiologist needs to knowSubsequent intra-abdominal fibromatosis mimicking recurrent gastrointestinal stromal tumor.Treatment of extra - abdominal desmoid tumors with chemotherapy.Desmoid tumors: need for an individualized approach.Targeted therapies: the rare cancer paradigm.Is wide resection obsolete for desmoid tumors in children and adolescents? Evaluation of histological margins, immunohistochemical markers, and review of literature.Immunohistochemical and mutational analysis of PDGF and PDGFR in desmoid tumours: is there a role for tyrosine kinase inhibitors in c-kit-negative desmoid tumours?Antitumor effects of hyaluronan inhibition in desmoid tumors.Concurrent Imatinib and Radiation Therapy for Unresectable and Symptomatic Desmoid Tumors.Mesenchymal stromal cell mutations and wound healing contribute to the etiology of desmoid tumors.Complete response to exemestane in a patient with a desmoid tumor.Management of desmoid tumours: A large national database of familial adenomatous patients shows a link to colectomy modalities and low efficacy of medical treatments.Positron emission tomography as a surrogate marker for evaluation of treatment response in patients with desmoid tumors under therapy with imatinib.When is a GIST not a GIST? A case report of synchronous metastatic gastrointestinal stromal tumor and fibromatosis.Reactivation of chronic hepatitis B infection related to imatinib mesylate therapyDesmoid Tumors: A Clear Perspective or a Persisting Enigma? A Case Report and Review of Literature.
P2860
Q21245591-9A85AC53-CACE-43CC-81ED-12BC0C771340Q30463805-AEF22E3A-954B-410D-B3EA-23A7B5B23088Q33737479-99C2CB22-E07D-4E8E-9C3D-CABE68312B26Q33747261-9001BF50-E052-460A-9ACD-3DD43F3A5491Q34023059-6ED6D4C4-AA34-4CCF-B193-3CB98FB165FEQ34129408-30F64B78-E6C8-4EBA-B7BC-E2EAE32BAACDQ34553335-8E762DDD-1294-486C-9A32-4B4CA4AD8ED3Q34607838-CCBCDA13-05BB-4C2B-8388-D3138BBDDDDDQ34627990-C1B310C0-2696-498E-8EA8-DC962B6A6B12Q34628337-93F6D1C2-5A22-45AA-92D9-5CA09B7A7361Q34670501-9EAEA640-23CE-44B8-891F-77697C15C9BCQ34761450-01C3CD9A-9AC6-4444-A6D8-B315C9A27A51Q34782409-144A2BC2-076D-409B-9DEA-416F6B67257FQ35016339-126EA077-2897-4642-AE7F-3ECA1B0008DAQ35588802-9EA4444B-4E4B-4882-A821-058A1B6ED6ACQ35597084-1942960E-3B8A-4354-BE0B-6DAD51AFEA99Q36028660-FDE737B2-03A7-4FF7-BA47-56DBF05714CCQ36131094-4FDABF85-9677-40E0-9C96-D0C8A2A83F11Q36167287-2B382416-676A-4596-A8E2-6C2C6203DFC5Q36253804-167BDE30-3366-48BE-AB3C-B6466A5ABDB3Q36383438-B798FB10-0992-41CE-8DE1-7E72A31D1E3EQ36536625-B7F91FA8-EF39-46F3-83CC-4580D565F5EEQ36674228-6AE9BE4B-786E-46F9-AFA3-D539F06CC59DQ36735332-3A6BD9AE-7048-4220-9B09-74101F964B68Q36819466-210C719C-177E-41A4-AF5B-6340166DD3A6Q37114694-002153E3-AD77-431B-B5E0-C81B120FC6AEQ37137419-5649A296-655D-47A1-B652-F218A6DB7BD6Q37449070-0E921217-3978-4C69-ABA7-B2EC05406CFCQ37632825-67925C50-3F34-46FC-B518-BE2846F98510Q38255180-F3BC6F18-5F29-4847-96C0-EA3D5C3A0F35Q38434898-85F05209-1A33-4645-AE77-F85077CC0F63Q39065008-F95F797F-E5CE-4D64-9852-D2B5CAA1ED40Q39152035-4562C211-1DCE-4800-A487-8740F1076276Q39441246-0AE39C7A-053F-434D-A454-97A0526155C7Q39627437-497297A2-1A3C-4879-A470-7AE66663F1D8Q41302922-77256613-CC9E-40AB-AA6C-43C3409F477CQ41462626-54C8615B-57CF-4478-8861-D2EF42030BDCQ41863750-0E508535-CA6E-4514-9BE7-82756C443B1FQ41892625-7D5F1B15-9EE1-40BD-B481-8A08A258CDDDQ42286668-63738126-17EF-4624-9B90-991B10342CC1
P2860
Response of extraabdominal desmoid tumors to therapy with imatinib mesylate.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Response of extraabdominal desmoid tumors to therapy with imatinib mesylate.
@en
Response of extraabdominal desmoid tumors to therapy with imatinib mesylate.
@nl
type
label
Response of extraabdominal desmoid tumors to therapy with imatinib mesylate.
@en
Response of extraabdominal desmoid tumors to therapy with imatinib mesylate.
@nl
prefLabel
Response of extraabdominal desmoid tumors to therapy with imatinib mesylate.
@en
Response of extraabdominal desmoid tumors to therapy with imatinib mesylate.
@nl
P2093
P356
P1433
P1476
Response of extraabdominal desmoid tumors to therapy with imatinib mesylate.
@en
P2093
Cornelius McGinn
Curtis Hayes
Dafydd Thomas
J Sybil Biermann
Joseph Mace
Laurence Baker
Vernon Sondak
P304
P356
10.1002/CNCR.11029
P407
P577
2002-12-01T00:00:00Z